OncLive® provides updates on the treatment of patients with diffuse large B-cell lymphoma through a Scientific Exchange Workshop.
Expert Perspectives in the Evolving Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Faculty debate the definitions of chemotherapy resistance, sensitivity, and refractoriness and discussed appropriate management strategies based on how patients would be classified in DLBCL.
Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recent trials of novel therapies and therapeutic combinations have introduced promising options for the management of patients with relapsed or refractory diffuse large B-cell lymphoma.
Dr. Kahl on the Utility of Tafasitamab/Lenalidomide in DLBCL
Brad S. Kahl, MD, discusses the utility of tafasitamab combined with lenalidomide in patients with diffuse large B-cell lymphoma who are ineligible for CAR T-cell therapy.
Dr. Abdulhaq on the Benefits of Chemotherapy-Free Options in DLBCL
Haifaa Abdulhaq, MD, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma.
Dr. Flinn on Opportunities for Second-Line Tafasitamab in DLBCL
Ian W. Flinn, MD, PhD, discusses the opportunity for second-line tafasitamab (MOR208, formerly Xmab®5574) as a palliative treatment of patients with diffuse large B-cell lymphoma.
Dr. Abdulhaq on the Safety Profile of Tafasitamab in DLBCL
Haifaa Abdulhaq, MD, discusses the safety profile of tafasitamab (MOR208) in diffuse large B-cell lymphoma.
Dr. Kahl on Findings From the L-MIND Study With Tafasitamab in DLBCL
Brad S. Kahl, MD, discusses findings from the phase 2 L-MIND study in diffuse large B-cell lymphoma.
Dr. Flinn on the Utility of Tafasitamab in Relapsed/Refractory DLBCL
Ian W. Flinn, MD, PhD, discusses the utility of tafasitamab (MOR208) in patients with relapsed diffuse large B-cell lymphoma (DLBCL).
MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma
PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma
Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer
Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC